Citations

Clear

3138 citation(s) found for "Smith, AM".

A Comprehensive Analysis on the Impact of Hypothermic Machine Perfusion and its Influence on Delayed Graft Function
Li, Zhihao , Mahgoub, Mohammed, Alrifai, Ahmed, Ryan, Randi J. , Issa, Naim , Mahgoub, Mohammed Y, Alrifai, Ahmed Zeen Alabedeen, Cortez, Alexander R. , Li, Zhihao , Smith, Byron H. , Mour, Girish , Jadlowiec, Caroline C. , Riad, Samy

Mayo Clinic

Transplantation Direct | November 7, 2025 | Volume: 11 | Issue: 12 | Pages: e1875

10.1097/txd.0000000000001875 | PMID 41209481 Get It

Background. Delayed graft function (DGF) in deceased-donor kidney transplantation increases morbidity, prolongs hospitalization, and increases healthcare costs. Hypothermic machine perfusion (HMP) has emerged as a promising strategy to reduce DGF; however, large-scale real-world data remain limited. Methods. We performed a retrospective cohort analysis using the Scientific Registry of Transplant Recipients (2014–2024), including adult dialysis-dependent recipients of deceased-donor kidneys preserved using either static cold storage (SCS) or HMP. The primary outcome was DGF, defined as dialysis requirement within 7 d posttransplant. A matched-pairs analysis was conducted using kidneys from the same donor. Results. The overall cohort included 59 859 recipients (46.8% SCS, 53.2% HMP), with 2208 matched pairs identified. In the overall cohort, HMP grafts had longer cold ischemia times and a higher kidney donor risk index. They were more frequently obtained from older and donation after circulatory death donors. Although the overall DGF incidence was higher with HMP (34.4% versus 30.9%, P < 0.001), matched-pairs analysis revealed significantly lower DGF rates with HMP (29.8% versus 36.1%, P < 0.001). Adjusted analyses identified HMP as protective against DGF (overall cohort odds ratio, 0.71; 95% confidence interval, 0.66-0.78; paired cohort OR, 0.68; 95% CI, 0.50-0.93). Additional modifiable risk factors include prolonged cold ischemia time, higher recipient body mass index, and longer dialysis duration. Conclusions. This real-world study demonstrates that HMP is associated with a significant reduction in DGF risk in kidney transplantation compared with SCS, supporting its broader implementation and targeted management of modifiable risk factors.
Senotherapeutics for metabolic disease and diabetic complications
Chaib, Selim , Suda, Masayoshi , Smith, Ulf , Kirkland, James L. , Chaib, Selim , Suda, Masayoshi , Smith, Ulf , Palmer, Allyson K. , Spinelli, Rosa , Prata, Larissa , Tchkonia, Tamar

Mayo Clinic

Journal of Internal Medicine | November 5, 2025 | Volume: 299 | Issue: 1 | Pages: 2-19

10.1111/joim.70039 | PMID 41189469 Get It

Abstract Metabolic diseases, including obesity, Type 2 diabetes (T2D), and metabolic syndrome, are increasingly prevalent worldwide, driven by sedentary lifestyles, aging populations, and complex genetic and environmental factors. Traditionally understood as disorders of glucose and lipid metabolism, a growing body of evidence now implicates cellular senescence as a central, age‐related contributor to metabolic dysfunction. Senescent cells (SCs) accumulate in key metabolic tissues where they disrupt tissue function through the senescence‐associated secretory phenotype (SASP), a pro‐inflammatory and fibrogenic secretome. SASP factors exacerbate insulin resistance, chronic inflammation, and tissue remodeling, advancing the progression and complications of metabolic diseases. These insights have catalyzed the development of senotherapeutics, a class of interventions that includes senolytics (to eliminate SCs), senomorphics (to suppress SASP), and senosensitizers (to render resistant SCs more vulnerable to clearance). Although preclinical studies show promise, translation into clinical practice faces significant challenges, including identifying reliable biomarkers, understanding SC heterogeneity, and optimizing treatment timing and safety. As research advances, senotherapeutics may offer a transformative approach not only to managing metabolic diseases but also to mitigating associated comorbidities. The recognition that antidiabetic agents already in clinical use can modulate key features of senescence highlights a unique translational opportunity, suggesting that prevention of age‐related metabolic disorders may be achievable with therapies already available in routine clinical practice. Medicine is poised to enter a new era in which targeting cellular senescence could fundamentally reshape the prevention and treatment of age‐related metabolic disorders, offering the potential for improved healthspan and reduced disease burden across the lifespan.
844 Immune cell profile changes in patients treated with tarlatamab for extensive-stage small cell lung cancer in real world practice
Ma, Audrey, Corraes, Andre De Menezes Silva , Wu, Chen , Shao, Zuoyi , Regan, Kevin M., Karam, Dhauna , Potter, Ashley , Al‐Ajmi, Abdullah, Mina, Syeda A. , Taylor, Skyler, Parikh, Kaushal , Shanshal, Mohamed , Luce, A., Schwecke, Anna, Lin, Yi , Leventakos, Konstantinos , Taylor, Skyler J, Hazim, Antonious , Dimou, Anastasios , Molina, Julian, Mansfield, Aaron S. , Smith, Katherine E.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A953-A954

10.1136/jitc-2025-sitc2025.0844 Get It

2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Aranow, Cynthia , Barnado, April , Broder, Anna , Chowdhary, Vaidehi , Hersh, Aimee O. , Jules, Marimee, Kalunian, Kenneth , Smith, Benjamin J. , Smith, Natalie, Thomas, Asha , Timlin, Homa , Bartels, Christie M. , Cunha, Joanne S., DeQuattro, Kimberly , Gomes, Laís Lopes Almeida , Cuéllar‐Gutiérrez, María C. , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kimberly P. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Chong, Benjamin F , Hersh, Aimee O , Rubinstein, Tamar B , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Gomes, Lais Lopes Almeida , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Liang, Kimberly P , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Sammaritano, Lisa R , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Werth, Victoria P. , Chong, Benjamin F. , Izmirly, Peter , Jules, Marimee, Kamen, Diane L. , Thomas, Asha, Azzam, Muayad , Fava, Andrea , Figueroa‐Parra, Gabriel , Garg, Shivani , Kawtharany, Hassan , Mustafa, Reem A

Mayo Clinic

Arthritis & Rheumatology | November 4, 2025 | Volume: 78 | Issue: 7 | Pages: 1361-1386

10.1002/art.43452 | PMID 41187097 Get It

Objective To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. Methods Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. Results We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities. Conclusion This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.
2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Aranow, Cynthia , Barnado, April , Broder, Anna , Chowdhary, Vaidehi , Hersh, Aimee O. , Jules, Marimee, Kalunian, Kenneth , Smith, Benjamin J. , Smith, Natalie, Thomas, Asha , Timlin, Homa , Cunha, Joanne S., DeQuattro, Kimberly , Gomes, Laís Lopes Almeida , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kimberly P. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Chong, Benjamin F , Hersh, Aimee O , Rubinstein, Tamar B , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Gomes, Lais Lopes Almeida , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Liang, Kimberly P , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Sammaritano, Lisa R , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Werth, Victoria P. , Chong, Benjamin F. , Izmirly, Peter , Kamen, Diane L. , Thomas, Asha, Azzam, Muayad , Bartels, Christie M. , Fava, Andrea , Figueroa‐Parra, Gabriel , Garg, Shivani , Cuéllar‐Gutiérrez, María C. , Kawtharany, Hassan , Mustafa, Reem A

Mayo Clinic

Arthritis Care & Research | November 3, 2025 | Volume: 78 | Issue: 7 | Pages: 815-839

10.1002/acr.25690 | PMID 41182321 Get It

Objective To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. Methods Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. Results We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities. Conclusion This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.
A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development
Garg, Shivani , Hartel, Izzy, Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Rovin, Brad H. , Turner, Amy S. , Williams, Bené, Ung, Brian , Bhavsar, Hiya, Gore‐Massy, Monique , Pulido, Nahirannette, Guerrero, N Hernandez, Smith, Natalie, Machua, Wambui, Hiraki, Linda T. , Rovin, Brad H , Turner, Amy S , Hiraki, Linda T , Duarte-García, Alí , Garg, Shivani , Sammaritano, Lisa R , Askanase, Anca , Bermas, Bonnie , Werth, Victoria P. , Mustafa, Reem A , Williams, Bené, Pulido, Nahirannette, Guerrero, Natacha, Son, Mary Beth F.

Mayo Clinic

Arthritis Care & Research | November 3, 2025 | Volume: 78 | Issue: 7 | Pages: 925-935

10.1002/acr.25693 | PMID 41182325 Get It

Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN) and 2025 SLE screening, treatment guidelines. Methods We completed a cross‐sectional qualitative study using content analysis of two Patient Panel meetings for the ACR LN and SLE guidelines. Key themes were presented by Patient Panel representatives during Voting Panel Meetings along with evidence for each recommendation, to ensure comprehensive discussions and align treatment recommendations with patients’ priorities and values. Results Nineteen people (90% women) with diagnoses of SLE and/or LN participated in the Patient Panels and 17 consented to use their feedback for analysis. Thematic analysis of their discussions revealed nine patient‐reported key themes in three domains: (1) treatment and monitoring of LN and SLE: medication side effects, daily function, treatment goals, and monitoring and screening; (2) clinical communication: strategies to optimize communication and provider and structural impediments to effective communication; and (3) improving transparency and information sharing: clinical trial participation, and medical costs and insurance coverage. These themes were actively incorporated into discussions during the Voting Panels for the ACR LN and SLE guidelines. Conclusion This work supported the integration of patient experiences in the clinical practice guideline development process and aligned recommendations with real‐world patient experiences and priorities, thereby enhancing the clinical applicability of the ACR LN and SLE guidelines. image
Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Lazare, Seka , Gu, Zhuosheng , Earland, Noah , Harmon, M. , Pacula, Maciej , Rivera, Megan , Tellis, Ashley , Whitfield, Damion , Benson, Adam , Gerndt, Sophie P. , Khalil, Lucien , Xu, Zhongping , Wahle, Benjamin M. , Zandberg, Dan P. , Spector, Matthew E. , Seethala, Raja R. , Smith, Joshua D. , Greer, Amy , Verner, Ellen L. , Georgiadis, Andrew , Ramkissoon, Shakti , Jensen, Taylor J. , Francis, Marra S. , Winckler, Wendy , Chaudhuri, Aadel A. , Harmon, Michael A , Gerndt, Sophie , Harris, Peter K , Khalil, Lucien , Ramirez, Ricardo , Xu, Zhongping , Wahle, Benjamin , Puram, Sid , Adkins, Douglas , Thorstad, Wade , Zandberg, Daniel , Chernock, Rebecca , Skinner, Heath Devin , Spector, Matthew E , Seethala, Raja , Ferris, Robert L , Smith, Joshua D , Greer, Amy E , Verner, Ellen L , Georgiadis, Andrew , Sausen, Mark , Ramkissoon, Shakti H , Jensen, Taylor J , Francis, Marra S , Winckler, Wendy , Chaudhuri, Aadel A , Zevallos, Jose , Rivera, Megan , Adkins, Douglas R. , Ferris, Robert L. , Zevallos, Jose P.

Mayo Clinic

Clinical Cancer Research | November 3, 2025 | Volume: 32 | Issue: 1 | Pages: 135-147

10.1158/1078-0432.ccr-25-1221 | PMID 41182409 Get It

Abstract Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.
Abstract 4365867: Atherosclerotic Cardiovascular Disease Score Underpredicts Five-Year Cardiovascular Risk After Sepsis: External Validation
Delgado, J. Fernández , Pareek, Aayushi , DAPKE, KARTIK, Alaws, Hossny, López, Félix Eduardo Lugo , Bateh, Said , Jena, Anek , Saleem, Faiz , Smith, Jeff , Reddy, Swetha , Patel, Neal M. , Sanghavi, Devang , Soto, Jose Soto , Huespe, Iván

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4365867 Get It

Background: Sepsis survivors experience substantial long-term cardiovascular (CV) morbidity and mortality. The pooled-cohort atherosclerotic cardiovascular disease (ASCVD) score estimates 10-year risk in the general population, but its accuracy soon after sepsis is unknown. Objectives: (1) Describe the absolute five-year incidence of major adverse cardiovascular events (MACE) after sepsis hospitalization. (2) Evaluate the discrimination and calibration of the 10-year ASCVD score for predicting five-year MACE in this setting. Research Questions: The ASCVD score would underpredict five-year MACE in sepsis survivors, reflecting their heightened risk. Methods: We performed a retrospective closed-cohort study using electronic health records from Mayo Clinic hospitals (USA). Adults aged 40–75 years hospitalized for sepsis between 2018 and 2020 were eligible if follow-up was ≥5 years; the age criterion matched the derivation range of the ASCVD score. The primary outcome was five-year MACE—myocardial infarction (MI), ischemic or hemorrhagic stroke, or CV death. Secondly we evaluated the predictive performance of ASCVD score for five-year MACE. Discrimination was assessed with the area under the receiver-operating curve (AUROC); calibration with Calibration-in-the-Large (CITL, ideal = 0) and slope (ideal = 1). Performance metrics were calculated in patients with complete ASCVD variables. Results: A total of 6306 sepsis admissions were screened. 2424 patients were excluded for age outside 40–75 years and 879 for <5 year follow-up, leaving 2718 patients for incidence analyses. Median age was 65 years (IQR 56–70); 55 % were male, 38 % required ICU care, and 91 % were White. Median body-mass index was 28.2 kg/m2 (IQR 23.7-34.7). During follow-up, 125 patients (4.6 %) had MI, 219 (8.1 %) experienced stroke, and 303 (11.1 %) died of CV causes; overall, 1573 patients (57.9 %) met the composite MACE outcome. Complete ASCVD data were available for 409 patients. In this subset, discrimination was moderate (AUROC 0.65; 95 % CI 0.59–0.71). Calibration showed CITL +0.34 (95 % CI 0.09–0.59) and slope 0.50 (95 % CI 0.28–0.72), indicating systematic infra-prediction and over-fitting, respectively. Conclusion: Five-year MACE incidence after sepsis is high. The 10-year ASCVD score moderately discriminates but underestimates five-year CV risk in this population, highlighting the need for sepsis-specific predictive models or recalibration to guide targeted post-sepsis cardiovascular prevention.
Abstract 4366183: Development of a High-Throughput Drug Screening Platform to Identify Novel Therapeutics for Long QT Syndrome
Zhou, Wei , Ye, Dan , Tester, David J. , Giudicessi, John, Smith, Annabel, Kim, Changsung, Giudicessi, John R. , Ackerman, Michael

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4366183 Get It

Background: Long QT syndrome (LQTS) is a potentially lethal cardiac channelopathy that stems primarily from pathogenic variants in KCNQ1 (LQT1), KCNH2 (LQT2), or SCN5A (LQT3) and is characterized by prolongation of the cardiac action potential duration (APD) at the cellular level. Despite current therapeutic options, there is a pressing need for novel, precision medicine-based, effective pharmacological therapies for LQTS, particularly for LQT2 and LQT3. Goal: To develop a high-throughput drug screening platform to identify novel therapeutics for LQTS using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Methods: iPSC-CMs were made for patients with LQT2 (p.G604S) or LQT3 (p.P1332L). Voltage dye assays were performed using a kinetic image cytometer (KIC) in a 96 well format. The APD at 90% repolarization (APD90) was measured in treated/untreated iPSC-CMs. Cyteseer image analysis software was used for optical APD analysis. SCN5A-P1332L iPSC-CMs were treated with 10 uM mexiletine (MEX) as a positive control. 114 compounds from a commercially available library of FDA-approved drugs were tested in triplicate to assess their APD shortening efficacy. Whole-cell patch clamp was used to confirm the lead compound’s effect in KCNH2-G604S iPSC-CMs. Results: MEX significantly shortened the APD90 of SCN5A-P1332L iPSC-CMs by 13% (669 ± 5 to 586 ± 10 ms; p<0.0001; n=50). Of the 114 tested compounds, 6 shortened the APD90 of SCN5A-P1332L iPSC-CMs by greater than 20%. The lead compound shortened the APD90 of SCN5A-P1332L iPSC-CMs by 32% (571 ± 2 ms; n=314, to 387 ± 4 ms; n=80; p<0.0001). All 6 candidate compounds also shortened the APD90 of KCNH2-G604S iPSC-CMs by greater than 20% in KIC screening assays. Whole-cell patch clamp confirmed APD shortening by the lead compound in KCNH2-G604S iPSC-CMs (759 ± 35 ms; n=13, to 599 ± 89 ms; n=9; p<0.03). Conclusion: The high-throughput KIC screen confirmed mexiletine’s APD shortening effects in SCN5A-P1332L iPSC-CMs, validating the assay's potential for efficient, large-scale drug screening. In a pilot screen, we identified 6 novel LQTS drug candidates which shortened the APD90 in SCN5A-P1332L (LQT3) and KCNH2-G604S (LQT2) iPSC-CMs more than mexiletine. The lead compound’s APD shortening effects in KCNH2-G604S iPSC-CMs were confirmed with whole cell patch clamp. The KIC platform offers a robust method for identifying novel QT shortening compounds by enabling reproducible APD measurements in a high-throughput format.
Abstract 4361649: Polysocial Risk Scores and Genetic Risk Factors Are Independently and Additively Associated with Cardiometabolic Diseases Across Self-Identified Race/Ethnicity Groups
Hamed, Marwan , Etheridge, Bethany, Espinoza, Angelica, Hakonarson, Hakon, Irvin, Ryan, Khan, Atlas , Namjou, Bahram , Landry, Latrice , Limdi, Nita A. , Sabatello, Maya , Tiwari, Hemant , Walunas, Theresa L. , Wei, Wei‐Qi, Wiesner, Georgia L. , Rowley, Robb , Manolio, Teri A. , Sharp, Richard R. , Kullo, Iftikhar, Sharp, Richard R , Walunas, Theresa L , Naderian, Mohammadreza , Smith, Johanna L. , Dikilitas, Ozan , Brokamp, Cole , Chaiyachati, Barbara H. , Chisholm, Rex L. , Clayton, Ellen Wright , Connolly, John J. , Davis, Brittney H. , Feng, QiPing , Hakonarson, Hakon, Holm, Ingrid A. , Jarvik, Gail P. , Kottyan, Leah C. , Luo, Yuan , Rasmussen‐Torvik, Laura J. , Tiwari, Hemant

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4361649 Get It

Background: Susceptibility to cardiometabolic diseases (CDs) is shaped by genetic, socio-environmental, and lifestyle factors. We evaluated the associations of disease-specific polysocial risk scores (PSSs)— derived from social determinants of health (SDOH) and lifestyle factors—and genetic risk factors with six CDs, across self-identified race/ethnicity (SIRE) groups in the eMERGE IV cohort. Methods: The six CDs included: atrial fibrillation, coronary heart disease, chronic kidney disease, hyperlipidemia, obesity, and type 2 diabetes. Disease-specific PSSs were developed using machine-learning models based on 65 SDOH and lifestyle factors. Participants were grouped based on their SIRE as Asian, Black, Hispanic/Latino, and White. We evaluated PSS distributions across SIRE groups. Genetic risk was assessed through disease-specific polygenic risk scores (PRSs), monogenic etiologies, and family history (FamHx). High PSS and high PRS were defined as the top 5th percentile. Associations were tested using multivariable logistic regression; model performance was assessed using the C-statistic. Results: Among 20178 participants (50±15 years, 68% female, 40% non-White), the most frequently associated PSS components were physical activity, sleep, self-perceived health, and income. PSS distributions varied across SIRE groups, with Whites having the lowest and Black and Hispanic/Latinos the highest scores for most CDs (Figure 1). All PSSs were significantly associated with their respective CDs, independent of confounders (OR per 1 SD increase: 1.19–2.68; Figure 2-A). No significant interactions were observed between PSSs and PRSs or monogenic etiologies. However, significant interactions were noted between PSSs and FamHx for CKD and obesity. PSS and PRS effects on the odds of CDs were independent (Figure 2-B) and additive (Figure 2-C). Incorporating PSSs into models that included clinical and genetic risk factors improved predictive performance of risk prediction models (Figure 3). Conclusion: PSSs, reflecting socio-environmental and lifestyle disadvantage, varied significantly across SIRE groups and were associated with risk of six CDs, independent of and additive to PRS. Given the substantial variation in socio-environmental and lifestyle risks across SIRE groups, integrating these factors into risk prediction models for CDs may help address health disparities and enhance preventive efforts, especially in marginalized populations.